
The Life Science Barometer is an annual survey
highlighting key trends and needs of the industry.
It takes 10 minutes to complete.

“The Barometer provides a clear and useful picture of the state of the life sciences industry and a trend forecast. We in the Life Science Office need this together with other information to be able to be as relevant and strategic as possible in our information to the responsible ministers. We are therefore grateful to all companies and stakeholders who choose to contribute to it. A copy of the latest Barometer is always on my desk!”
Jeanette Edblad
Director of the Swedish governments Office for Life Sciences.


The 2023 survey resulted in the
Life Science Barometer 2024,
a data-rich and facts-based
presentation of the industry
“Data generates insights, so the more and better data we have about our industry, the smarter decisions can be made both in the boardroom and in Parliament. The information provided by the Life Science Barometer is invaluable to all stakeholders and helps to drive our industry forward. The contribution each company makes by responding to the survey is small compared to the overall benefit of the results, so I encourage you all to make a contribution.”
Anders Persson
Head of Ecosystem Strategy & Projects,
BioVenture Innovation Unit, Astra Zeneca
and chairman of the board, SwedenBIO.

FAQ
What is the purpose of the survey?
To promote and strengthen the Swedish life science industry by providing data for informed decisions and international comparisons.
Who should respond?
Top management persons in companies and organisations within the life science sector. We also welcome companies supporting the life science sector, such as service providers, investors etc. We use the definition of life sciences as presented in the Swedish life science strategy from 2019, with a focus on supporting human health.
What is the focus for the 2024 survey?
This year’s focus is on value generation. What value does the Swedish life science industry provide, and what is needed to keep it running?
What kinds of questions are there?
The survey is a combination of questions to gather facts as well as opinions and trends. All responses regarding opinions and future outlooks will be kept strictly confidential and only published at an aggregated level. The results from the questions labeled Facts for database will be made publicly available through the database Insight Machine.
What is Insight Machine, and how is it linked to the Barometer?
This year, the survey is taking place within Insight Machine, which is a publicly available interactive database of the Swedish life science industry, provided and curated by STUNS. SwedenBIO works in partnership with STUNS to improve the overall availability of data about the industry. The Barometer survey is one source of updated company information to Insight Machine.
Rest assured, we handle your survey responses with strict confidentiality. We only make the data from questions marked “Result to database” available in the database.
How will the results be used?
The results from the Barometer will be published in a digital report describing the national perspective at the SwedenBIO summit December 11, 2024. Following the national report, we plan to create regional reports highlighting regional strengths and focus areas. We intend to spread the results through various channels to audiences within Sweden and abroad.
What happened with the results from the previous Barometer?
The survey performed in October 2023 resulted in the Barometer 2024 report, which has been used for informed decisions and data-driven discussions throughout the year.
Thank you!
The following companies have completed the survey.
4L Bioconsulting | FIA | Abilion Medical Systems | Adlersson Heath |
Alder Therapeutics | AlzeCure Pharma | Apotek Produktion & Laboratorier | Ascelia Pharma |
Bio-Works Sweden | BioReperia | Cantargia | Carmeda |
Cordator Life Science | CuraCell | Curovir | Devyser Diagnostics |
Empros Pharma | Enginzyme | Envue Technologies | Evi-networks |
Fåhraeus startup and growth | GBA Key2Compliance | Gesynta Pharma | iCoat Medical |
ImaGene-iT | Isofol Medical | Lablytica Life Science | Lead Biologics International |
LINK Medical Research | Medeon Science Park & Incubator | Novo Nordisk | Orexo |
Pelago Bioscience | Pharma Way | Pharmista Technologies | QuRable |
Red Glead Discovery | Salipro Biotech | Scantox Sweden | Sound Bioventures |
Spago Nanomedical | Testa Center | Toxicology Knowledge Team Sweden | Valneva |
Abera Bioscience | AQILION | Attgeno | Beactica Therapeutics |
Blood Simpling | Calliditas Therapeutics | Gedea Biotech | HØIBERG |
Heartrunner Sweden | Histogol | Lipum | Medicon Village Innovation |
Melius Pharma | MERAccess | Neola Medical | NorthX Biologics |
omnio | Seanalytics | SWIPP | Thioredoxin Systems |
Vivolab | VOC Diagnostics | Anamar | Atlas Antibodies |
Beat Vascular Health | BeePCo | Berner | Berry Lab |
BioLamina | Bonnier Healthcare | BrainZell | CareLigo |
Carl Bennet | Cavidi | Cell4Cure | CR Competence |
Cytel Sweden | Cytiva | DanPET | Digital Trial Consultants |
Edvonova | Elevation State | European Spallation Source | Exeltis Sverige |
Fluicell | Goodsomnia | Gradientech | Hameln pharma |
Hemsö | Holtra | Iconovo | inorbit therapeutics |
Invivopower | Larodan | Lipidor | Medarca |
Medical Innovation Design | MedVasc | Milmed Unico | Naslund Medical |
Navinci | Neobiomics | Neosense Technologies | Nordlander4H |
Novus Scientific | Olink | Oxcia | Paindrainer |
PExA | PharmNovo | Phase2Phase Biopharma Consulting | Phenaros Pharmaceuticals |
Potter Clarkson | Probingon | Rarity Bioscience | Reccan |
Recordati | Resitu Medical | Ridgeview Instruments | Sangair |
SARomics Biostructures | Sorbus Biomedical | Sprint Bioscience | Statistikkonsulterna Väst |
SwedenBIO | Thermo Fisher Scientific | Toleranzia | TuuLifeScience |
Vacara | Veranex Sweden | Waters | Willuhn Consulting |
Youni | Zelmic | Umeå Biotech Incubator (UBI) | AroCell |
AstraZeneca | Baxter | BioArctic | Biotage |
BMS | CCRM Nordic | Cheisi | Cord Communications |
Cutis Skin Health Sweden | CytaCoat | Diaprost | Disruptive Pharma |
Double Bond Pharmaceutical | edenceHealth | Extem Pharma | FarmPharma |
Fredersen Advokatbyrå | Fresnius Kabi | Fujirebio Diagnostics | Gasporox |
HepaPredict | HOIBERG | Intelligent Implants | IRLAB |
Manje Health | Merck Group | Norrneo | Offspring Biosciences |
Oncopeptides | Oncorena | PolyPeptide Laboratories | Promimic |
Psilox | Q-linea | Recipharm Pharmacveutical Development | Recipharm Uppsala |
Repiratorius | Roche | Sanofi | Stardots |
Strike Pharma | Svar Life Science | Truly Labs | VERIGRAFT |
Xinnate | Profundus | PharmaRelations | ANYO Labs |
CTC Clinical Trial Consultants | Stockholm Science City Foundation | Umeå Biotech Incubator (UBI) | Scandinavian Regulatory Services |
Alligator Bioscience | Antaros Medical | MyCural Therapeutics | Atrogi |
NextCell Pharma | EMERITI BIO | Helseplan Consulting Group | Immuneed |
Industrifonden | Key2Brain | Mabtech |